Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center.
recurrence
resection margin distance
survival
vulvar cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Aug 2023
15 Aug 2023
Historique:
received:
20
07
2023
revised:
11
08
2023
accepted:
14
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The aim of this study was to evaluate the impact of pathological tumor-free margin distance on survival in SCC patients treated with surgery alone. This retrospective study included 128 patients with node-negative disease that received no adjuvant treatment. Disease-free and overall survival were analyzed according to pathological tumor-free margin distance. The patients were subclassified into three resection margin category groups: "1 to 3 mm" (n = 42), ">3 to 8 mm" (n = 47) or ">8 mm" (n = 39). Thirty-nine of the 128 patients (30.5%) developed recurrent disease. Median follow-up for disease-free survival (DFS) was 6.49 years (95% CI 5.16 years; 7.62 years), and median follow-up for overall survival (OS) was 6.29 years (95% CI 5.45 years; 7.33 years). The 5-year DFS rate was 0.70 (95% CI: 0.62-0.79), and the 5-year OS rate was 0.79 (95% CI: 0.71-0.87). Regarding the survival outcome, there were no independent significant differences in either disease-free survival (DFS) ( The present study did not show a significant impact of pathological tumor-free resection margin distance following surgery in patients with node-negative SCC of the vulva (that did not receive adjuvant treatment) on disease-free and overall survival.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate the impact of pathological tumor-free margin distance on survival in SCC patients treated with surgery alone.
METHODS
METHODS
This retrospective study included 128 patients with node-negative disease that received no adjuvant treatment. Disease-free and overall survival were analyzed according to pathological tumor-free margin distance.
RESULTS
RESULTS
The patients were subclassified into three resection margin category groups: "1 to 3 mm" (n = 42), ">3 to 8 mm" (n = 47) or ">8 mm" (n = 39). Thirty-nine of the 128 patients (30.5%) developed recurrent disease. Median follow-up for disease-free survival (DFS) was 6.49 years (95% CI 5.16 years; 7.62 years), and median follow-up for overall survival (OS) was 6.29 years (95% CI 5.45 years; 7.33 years). The 5-year DFS rate was 0.70 (95% CI: 0.62-0.79), and the 5-year OS rate was 0.79 (95% CI: 0.71-0.87). Regarding the survival outcome, there were no independent significant differences in either disease-free survival (DFS) (
CONCLUSION
CONCLUSIONS
The present study did not show a significant impact of pathological tumor-free resection margin distance following surgery in patients with node-negative SCC of the vulva (that did not receive adjuvant treatment) on disease-free and overall survival.
Identifiants
pubmed: 37627138
pii: cancers15164110
doi: 10.3390/cancers15164110
pmc: PMC10452494
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Surg Oncol. 2015 Dec;41(12):1653-8
pubmed: 26507171
Cancers (Basel). 2022 Aug 29;14(17):
pubmed: 36077719
Acta Obstet Gynecol Scand. 2021 Aug;100(8):1520-1525
pubmed: 33811323
Int J Gynecol Cancer. 2022 Mar;32(3):332-337
pubmed: 35256420
Cancers (Basel). 2023 Jan 06;15(2):
pubmed: 36672338
J Cancer Res Clin Oncol. 2016 Feb;142(2):489-95
pubmed: 26498775
Eur J Cancer. 2016 Dec;69:180-188
pubmed: 27837710
Cancers (Basel). 2020 Nov 14;12(11):
pubmed: 33202675
Gynecol Oncol. 2013 Sep;130(3):545-9
pubmed: 23747330
Ann Surg Oncol. 2011 Dec;18(13):3811-8
pubmed: 21594705
Eur J Surg Oncol. 2019 Nov;45(11):2109-2114
pubmed: 31285094
Int J Gynecol Cancer. 2023 Jul 3;33(7):1023-1043
pubmed: 37369376
J Gynecol Oncol. 2016 Nov;27(6):e60
pubmed: 27550406
Minerva Obstet Gynecol. 2021 Apr;73(2):160-165
pubmed: 33306289
Arch Gynecol Obstet. 2022 Jan;305(1):233-240
pubmed: 34387725
Prev Med. 2022 Nov;164:107302
pubmed: 36240909
Eur J Cancer. 2016 Sep;65:139-49
pubmed: 27497345
Obstet Gynecol. 1983 Jan;61(1):63-74
pubmed: 6823350
J Obstet Gynaecol Res. 2021 Nov;47(11):3990-3997
pubmed: 34365709
Arch Gynecol Obstet. 2023 Jun;307(6):1677-1686
pubmed: 35608701
Gynecol Oncol. 1998 Oct;71(1):116-21
pubmed: 9784331
Gynecol Oncol. 2007 Mar;104(3):636-41
pubmed: 17095080